Elranatamab and Mezigdomide Combination Therapy

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Near Add Your Location

Sorting 4 by

University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.